HOLX (HOLX)

VolitionRX's Q2 earnings call highlighted significant scientific advancements, including strong validation data for their Nu.Q NETs assay for sepsis and progress in lung cancer detection and feline lymphoma tests. Despite these scientific successes and strategic collaborations, the company faces financial challenges, including flat quarterly revenue, ongoing cash constraints, and execution risks related to regulatory approvals and licensing deals. Investors are left to weigh the compelling innovation story against the company's funding needs and commercialization hurdles.

Carlyle Credit Income Fund (CCIF/CCID) reported its third-quarter 2026 results, showing net investment income of $0.07 per common share and a total weighted average GAAP yield of 10.44% on its CLO portfolio. The fund declared monthly common dividends of $0.06 per share for September, October, and November 2026, representing an annualized rate of 24.91%. CCIF's portfolio consists of 42 CLO holdings with exposure to 1,450 underlying obligors, and its net asset value per common share was $3.32 as of June 30, 2026.

VolitionRX (VNRX) reported a wider-than-expected loss and lower revenue for Q2 2026, causing shares to slip. Despite the financial miss, the company highlighted progress in reducing operating costs, advancing scientific data, and developing partnerships in sepsis, cancer, and veterinary diagnostics. Management indicated that revenue remains unpredictable and declined to provide full-year 2026 guidance, focusing instead on long-term strategic milestones and licensing agreements.

LivaNova reported record Q2 2026 revenue of $390.6 million and adjusted diluted EPS of $1.26, exceeding prior-year figures, driven by strong demand in Cardiopulmonary and Epilepsy segments. The company raised its full-year 2026 revenue guidance to 8%-9% growth and adjusted diluted EPS guidance to $4.30-$4.40, citing improved market share, Essenz upgrade cycles, and favorable Medicare reimbursement. LivaNova also announced a long-term supply agreement with Thermo Fisher Scientific for oxygenator components and provided updates on its innovation pipeline, including next-generation oxygenators and advancements in its Obstructive Sleep Apnea program.

QT Imaging Holdings Inc. (NASDAQ:QTI) has appointed Jason Dyer as Vice President Regional Sales East and Dave Reinhart as Vice President Regional Sales West, effective July 2026. These appointments mark a strategic shift from a distributor-led sales model to a direct sales approach for its Breast Acoustic CT Scanner, though it will continue working with NXC Imaging, Inc. The new team aims to strengthen customer engagement and support clinical adoption, with potential expansion of commercial resources in 2027 and a focus on developing quantitative imaging biomarkers and Software-as-a-Service offerings.